Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients

NCT01804829 is registered in ClinicalTrials.gov with Biotest Pharmaceuticals Corporation as lead sponsor.

NCT NCT01804829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01804829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Lead sponsor
Biotest Pharmaceuticals Corporation
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2013
Completion date
June 30, 2016
Enrollment
80 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c infection, hepatitis, viral, human, hepatocellular carcinoma, liver cirrhosis, viruses